Weekly-Round-Up-April 10th to April 16th
April 17th, 2023
HeartFlow, the pioneer in precision heart care, announced the completion of a $215 million Series F funding round led by Bain Capital Life Sciences, with participation from new investor Janus Henderson Investors and existing investors Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, and Wellington Management.
This fresh funding will allow HeartFlow to satisfy the increasing demand for its commercial products, support a growing body of clinical evidence, and advance its full product range, which will assist clinicians in diagnosing coronary artery disease (CAD) and guiding their treatment decisions.
Kite, a next-generation commerce firm focused on developing high-potential brands, announced the closing of a $200 million equity investment from funds controlled by Blackstone and founding partner Juxtapose. Rob Solomon, former CEO and Chairman of GoFundMe, will lead the company as Kite Co-Founder and CEO. He has over two decades of experience in product and business development, operations management, M&A, and brand launches.
Gigstreem, a prominent nationwide provider of high-quality residential and business broadband networks, announced a $59 million investment round. In Q1’23, Gigstreem raised $59 million in two different transactions, with all proceeds coming from its current investor base. The initial transaction, which brought up $19 million for Gigstreem, was led by Crestline Investors and involved participation from real estate technology venture capital firm RET Ventures as well as multifamily industry leaders Essex Property Trust and UDR; capital from this raise will help Gigstreem more quickly scale its growth and deploy internet services across the country.
Oshi Health, a virtual specialty care company that is transforming gastrointestinal (GI) health outcomes and economics, announced that it has raised $30 million in Series B funding led by Koch Disruptive Technologies (KDT), with existing investors Bessemer Venture Partners, Flare Capital Partners, Frist Cressey Ventures, CVS Health Ventures, and Takeda Digital Ventures joining.
Carbon robots, a pioneer in AI-powered robots, announced the completion of a $30 million Series C fundraising round.The money comes from Sozo Ventures, a new lead investor, as well as current investors Anthos Capital, Fuse Venture Capital, Ignition Partners, Liquid2 and Voyager Capital. The funds will be utilized to grow North American sales regions, optimize and scale manufacturing, develop new software and hardware solutions, and enter overseas markets. Carbon Robotics’ total funding now stands at $67 million, according to this current round of funding.
ID.me, an identity company that enables consumers to easily access online services and benefits while maintaining control over their personal data, announced today that it has raised $132 million in Series D funding, led by Viking Global Investors and including CapitalG, Morgan Stanley Counterpoint, FTV Capital, PSP Growth, Auctus Investment Group, Moonshots Capital, and Scout Ventures. The current round increases the company’s total investment to more than $240 million since its inception in 2010.
Altruist, the modern custodian developed solely for RIAs, has announced a fresh $112 million series D round of fundraising headed by Insight Partners, with new investor Adams Street Partners joining the round and prior investors remaining supportive. Bill McNabb, Ron Carson, and Marty Bicknell, among others, took part in the round.Altruist’s new fundraising complements a previously revealed $110 million series C raised in November 2021 by Declaration Partners, with participation from Venrock, Insight Partners, and Vanguard, bringing its total funding to more than $290 million.
Epic Sciences, Inc., a privately held diagnostics company, has concluded a $24 million Series G fundraising, bringing its total funding in the last year to $67 million. The funds raised in this latest round of private investment will be used to support the commercial infrastructure needed to commercialize DefineMBC’s three component tests, which collectively deliver a comprehensive blood-based biopsy result for patients with metastatic breast cancer. The investment was co-led by Deerfield Management and Arsenal Capital Partners, and it featured a large number of Blue Ox Healthcare Partners, Domain Ventures, and Labcorp shareholders.